País: Canadà
Idioma: anglès
Font: Health Canada
CODEINE PHOSPHATE
LABORATOIRE ATLAS INC
R05DA04
CODEINE
25MG
SYRUP
CODEINE PHOSPHATE 25MG
ORAL
500ML/2L
Narcotic (CDSA I)
OPIATE AGONISTS
Active ingredient group (AIG) number: 0104398001; AHFS:
MARKETED
1986-12-18
CODEINE PHOSPHATE SYRUP 5 mg/mL Page 1 of 31 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION N CODEINE PHOSPHATE SYRUP CODEINE PHOSPHATE 5 MG/ML (ORAL SYRUP) OPIOID ANALGESIC Laboratoire Atlas Inc, 9600, boul. des Sciences, Montréal, Québec, Canada, H1J 3B6 Date of Initial Approval: January 16, 2013 Date of Revision: August 30, 2018 Submission Control No: 213737 CODEINE PHOSPHATE SYRUP 5 mg/mL Page 2 of 31 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .................................................................. 4 1 INDICATIONS ................................................................................................................... 4 1.1 Pediatrics ................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ........................................................ 5 4 DOSAGE AND ADMINISTRATION .................................................................................. 6 4.1 Dosing Considerations ............................................................................................ 6 4.2 Recommended Dose and Dosage Adjustment ....................................................... 7 4.3 Administration .......................................................................................................... 8 4.4 Missed Dose ............................................................................................................ 8 4.5 Disposal ................................................................................................................... 9 5 OVERDOSAGE ................................................................................................................ 9 5.1 Symptoms: ..................... Llegiu el document complet